Revvity (RVTY): Recovery Story With Software Upside

Investment Summary

Thesis

Revvity(RVTY) fits a balanced, moderate-risk investment profile as a high-quality life sciences and diagnostics operator that is moving through a recovery phase rather than a clean breakout. The core case rests on four facts. First, the business produced $2.856B of 2025 revenue, split almost evenly between Life Sciences at $1.431B and Diagnostics at $1.425B, which gives it diversification across research and clinical end markets. Second, adjusted EPS reached $5.06 in 2025 and management guided 2026 pro forma adjusted EPS to $5.20 to $5.30 after Q1 2026, showing continued earnings growth despite portfolio changes. Third, free cash flow remains solid, with $515M reported for 2025 in company materials and a 6.78% FCF yield in the valuation data, which supports buybacks and selective M&A. Fourth, valuation is no longer demanding if forward earnings materialize, with a trailing P/E of 42.0 but a forward P/E of 16.1 and a PEG ratio of 0.53.

The stock is not a screaming bargain, but it does look mispriced relative to a business that has kept gross margin at 54.8%, generated $840.9M of EBITDA, repurchased over $800M of stock in 2025, and is building a more software-enabled workflow model. The catch is that Revvity is still carrying real friction: net debt was $2.60B at year-end 2025, GAAP net margin was only 8.5%, Diagnostics margins were pressured by tariffs, FX, and China, and the Street still leans cautious with 2 Buy and 7 Hold ratings in the supplied consensus. That combination argues for a Buy rather than a Strong Buy. The medium-term opportunity is a rerating toward the company’s improving earnings base as Diagnostics stays resilient, Life Sciences stabilizes, and software becomes a larger part of the mix.

Company Overview

Revvity(RVTY) is a Waltham, Massachusetts-based health sciences company with 11,000 employees and roots going back to 1937. The company changed its name from PerkinElmer to Revvity in April 2023, a move that reflected a portfolio shift toward life sciences tools, diagnostics, software, and workflow solutions. It operates in the Life Sciences Tools & Services niche within healthcare and sells instruments, reagents, software, subscriptions, services, and diagnostic products used by pharmaceutical and biotechnology companies, laboratories, academic institutions, public health authorities, private healthcare organizations, physicians, and government agencies.

The company’s structure is straightforward. In 2025, reported revenue totaled $2.856B, with Diagnostics contributing 49.9% and Life Sciences contributing 50.1%. That near-even split matters. It reduces dependence on a single funding stream and gives Revvity exposure to both research spending and clinical testing demand. The business model also has a recurring element that helps smooth volatility. Investor materials describe roughly 80% of revenue as recurring across consumables, services, and software, with about 20% tied to less recurring instrument demand. In plain English, the installed base matters. Once a lab adopts a workflow, the reagents, service contracts, and software renewals tend to keep showing up.

Management has also been actively reshaping the portfolio. In mid-January 2026, Revvity closed the acquisition of ACD Labs and began integrating it into the Signals software business. In Q1 2026, the company also shifted to pro forma guidance because it intends to divest its China Immunodiagnostics business, which represented about 6% of FY2025 revenue. That is not cosmetic housekeeping. It is a deliberate attempt to improve mix, simplify the story, and reduce exposure to a market that has been pressuring Diagnostics performance.

Business Segment Deep Dive

Life Sciences is the steadier but more cyclical half of Revvity’s portfolio. Full-year 2025 revenue was $1.431B, up 2% reported and 2% organic. In Q4 2025, Life Sciences generated $382M of revenue, up 2% reported and flat organic, with adjusted operating income of $136M and a 35.6% adjusted operating margin. That margin is still strong by most standards, even after slipping from 36.9% a year earlier. The segment includes Life Sciences Solutions and Software, and management said software growth added $35.6M in 2025, partly offsetting softness in other Life Sciences lines.

The internal mix inside Life Sciences is telling. Management said pharma and biotech sales rose low single digits in both Q4 and the full year, while academic and government sales declined low single digits. That split explains the segment’s muted top-line growth. Private-sector demand is improving first, while public and academic budgets remain slower. The more encouraging detail is that life sciences reagents and consumables were flat year over year in Q4 and instruments were also roughly flat after a strong double-digit sequential increase from Q3. After three years of heavier instrument weakness, flat is not exciting, but it is a lot better than falling down the stairs.

Diagnostics was the stronger engine in 2025. Full-year revenue reached $1.425B, up 5% reported and 4% organic. In Q4 2025, Diagnostics produced $390M of revenue, up 10% reported and 7% organic. The tradeoff is margin. Adjusted operating income was $91M in Q4, unchanged from the prior year, while adjusted operating margin fell to 23.4% from 25.7%. For the full year, Diagnostics adjusted operating margin declined to 24.2% from 26.1%. Growth is good, but not all growth is equally profitable.

Within Diagnostics, immunodiagnostics and reproductive health are the key pillars. Management said immunodiagnostics grew high single digits organically in Q4 and mid-single digits for the full year, with strong performance outside China partly offset by double-digit declines in China due to DRG-related volume pressure. Reproductive Health grew mid-single digits in Q4 and the full year, while newborn screening grew mid-single digits in Q4 and high single digits for the full year. That makes Diagnostics a mix of a healthy core business and one troublesome geography. The planned China Immunodiagnostics divestiture in 2026 lines up with that reality.

Flagship Product Analysis

Revvity has a broad catalog, but the most strategically important product family in the current story is Signals, the company’s software platform for scientific workflows. Management described Signals as embedded in nearly all major pharma companies around the world and said the business grew in the high teens organically for full-year 2025. In Q4, software was flat year over year because of renewal timing and difficult comparisons, but the underlying software metrics remained strong: nearly 40% ARR growth, SaaS representing about 35% of the business, double-digit APV growth, and net retention above 110%.

Those are the kinds of numbers that matter more than one quarter of reported revenue timing. ARR growth near 40% and net retention above 110% point to a product that is expanding inside customer accounts, not just surviving renewal season. Software also changes the quality of revenue. It raises recurring mix, improves visibility, and can support better valuation multiples than a pure instrument business. That is one reason the ACD Labs acquisition matters. Management expects ACD to contribute a little over $20M in 2026 and is integrating its offerings into the Signals One platform.

Outside software, newborn screening stands out as a flagship Diagnostics franchise. Management said newborn screening grew mid-single digits in Q4 and high single digits for full-year 2025, and that the reproductive health business has meaningfully outperformed underlying birth rate trends. That is a strong signal of execution and market position. In healthcare tools, outperforming the underlying procedure or population trend usually means the company is taking share, improving workflow adoption, or both.

Innovation & Competitive Advantage

Revvity’s competitive edge comes from workflow integration, recurring pull-through, and a growing software layer rather than from brute scale. Thermo Fisher(TMO) and Danaher(DHR) are larger, broader platforms. Revvity competes by being more focused in niches where integrated workflows matter, especially translational multi-omics, biomarker identification, reproductive health, immunodiagnostics, and informatics. The company’s own materials emphasize complete workflows from discovery to development, and diagnosis to cure. That language can sound polished to the point of overuse, but the underlying economics are real: instruments pull consumables, consumables pull services, and software ties the workflow together.

The Signals platform is central to that moat. Management said preclinical scientists work within Signals One every day to create data, analyze results, and share it with colleagues. That daily-use position matters because software embedded in research workflows tends to be sticky. Revvity is trying to deepen that position with Signals Synthetica, its AI models-as-a-service platform. The company also announced a collaboration with Lilly’s TUNE Lab initiative, and management said Lilly’s models are built on more than $1B of R&D investment over the last decade. That gives Revvity a credible AI angle that is tied to real scientific workflows rather than generic AI theater.

The company also benefits from IP, installed base, and global reach. Its 10-K says it relies on patents, trade secrets, know-how, continuing technological innovation, and licensing opportunities. It sells into more than 160 countries and serves pharma, biotech, labs, academia, and governments. None of those factors alone create an unbreakable moat. Together, they create switching costs and customer inertia, which is often enough in life sciences tools. Labs do not swap critical workflows casually. They do it when the pain of staying exceeds the pain of changing, and Revvity’s job is to keep that threshold high.

Operations & Supply Chain

Operations are a meaningful part of the Revvity story because management is using cost actions to protect margins while waiting for end markets to improve. In the Q4 2025 call, management said cost efficiency programs include footprint consolidations, deeper commercial and operational integrations, and greater supply chain and logistical synergies. These initiatives are expected to be fully completed by the end of Q2 2026. Management guided to 28% adjusted operating margin for 2026, up from 27.1% in 2025, with more of the benefit arriving in the second half.

That margin structure deserves attention. In 2025, tariffs, FX, and lower volume leverage pressured margins. Adjusted gross margin was 59.7% for the full year, down 160 bps, while adjusted operating margin fell 120 bps. Yet the company still generated $773M of adjusted operating income and $515M of free cash flow. This is not a business with a broken operating model. It is a business absorbing external pressure while keeping enough internal discipline to preserve cash generation.

The debt profile also helps on the operations side. Management said year-end net debt to adjusted EBITDA was 2.7x, 100% of debt was fixed rate, the weighted average interest rate was 2.6%, and average maturity extended another six years. That is a useful shield in a higher-rate world. There is a €500M bond maturing in July 2026 that management plans to retire, and it expects net interest and other expense to rise to $95M in 2026 from $84M in 2025. Even so, the financing structure remains manageable rather than stressful.

Market Analysis

Revvity operates inside a large and growing market. External market research in the supplied context places the global life science tools market around $153.8B in 2025, growing toward $230.1B by 2031, or about 6.9% CAGR. Revvity’s own Investor Day materials frame the Life Sciences opportunity at more than $30B overall, with Life Sciences Solutions alone at more than $25B. Against 2025 company revenue of $2.856B, that leaves plenty of room for share gains without heroic assumptions.

The more useful point is not just TAM size but market shape. Customers increasingly want integrated workflows, software, automation, and service layers rather than standalone instruments. That trend fits Revvity’s portfolio well. The company is not trying to win a commodity knife fight. It is trying to own more of the workflow, especially where data, software, and consumables reinforce one another. That is exactly where the industry is moving.

The market backdrop also has some cyclical support. Industry context cited life sciences deal value of $372B in 2025, up 47% year over year, and management said it is seeing modest improvement in pharma and biotech sentiment, stronger biopharma funding, and more M&A activity. Those are not abstract mood indicators here. Revvity directly sells into pharma, biotech, and preclinical research workflows, so healthier customer funding can translate into better instrument demand, stronger software adoption, and improved reagent pull-through.

Customer Profile

Revvity’s customer base is broad enough to reduce single-channel risk but concentrated enough in sophisticated buyers that execution matters. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. In Life Sciences, the most important split is between pharma/biotech and academic/government. In Q4 2025 and full-year 2025, pharma/biotech grew low single digits while academic/government declined low single digits.

That split says two things. First, Revvity is exposed to public funding cycles, and that remains a real risk. The company specifically cited NIH funding changes and the US government shutdown as headwinds. Second, the more commercially driven customer base is already stabilizing. That matters because pharma and biotech customers tend to be earlier adopters of workflow software, automation, and premium tools when budgets improve.

On the Diagnostics side, customer demand is tied more to clinical and public health workflows. Reproductive health and newborn screening are especially attractive because they are embedded in essential testing pathways. Management said reproductive health has outperformed underlying birth rate trends, helped by execution and Genomics England. That kind of customer relationship is sticky. Once a screening workflow is validated and embedded, replacement is slow and heavily scrutinized.

Competitive Landscape

Revvity competes in a crowded field that includes Thermo Fisher(TMO), Danaher(DHR), Agilent( A ), Bio-Rad(BIO), Merck KGaA, QIAGEN(QGEN), and Waters(WAT), along with diagnostics-focused players such as Abbott(ABT), Roche, bioMérieux, DiaSorin, QuidelOrtho(QDEL), Siemens Healthineers, and Werfen. The company’s 10-K says competition centers on service, price, innovation, operational efficiency, product differentiation, availability, quality, and reliability. That is management’s polite way of saying this is a serious market with no room for sleepy execution.

Revvity’s advantage versus the giants is focus. Its disadvantage is scale. Thermo Fisher and Danaher can outmuscle almost anyone on breadth, distribution, and capital. Revvity counters with sharper positioning in specific workflows and a more balanced mix of diagnostics and life sciences than some narrower peers. It also has a software asset in Signals that is strategically more important than its current revenue contribution suggests. Software can be the glue that keeps customers inside the broader ecosystem.

The missing piece in the supplied data is direct peer multiple comparison, so the clearest competitive conclusion comes from operations rather than headline valuation. Revvity’s 54.8% gross margin, 20.1% operating margin, 6.78% FCF yield, and high-teens software growth indicate a business with real differentiation, even if it lacks the scale premium of the largest peers. In practical terms, this is a credible second-line platform in a market where first-line giants dominate the headlines.

Macro & Geopolitical Landscape

Macro factors matter here because Revvity sits at the intersection of research budgets, healthcare policy, trade friction, and currency swings. Management explicitly cited NIH funding changes, tariffs, pharma policy uncertainty, the US government shutdown, foreign exchange movements, and DRG-related volume shifts in China as 2025 headwinds. Those were not small annoyances. They contributed to lower adjusted operating margin and pressured Diagnostics profitability.

China is the clearest geopolitical pressure point. Management said immunodiagnostics in China faced double-digit declines for the full year because of DRG-related volume pressure, and in Q1 2026 the company moved to pro forma guidance tied to its intended divestiture of China Immunodiagnostics, a business equal to about 6% of FY2025 revenue. That is a concrete example of portfolio management responding to policy risk. Sometimes the cleanest fix for a geopolitical headache is to stop owning the headache.

Currency and tariffs remain important. FX was a 1% tailwind to 2025 revenue and about a 2% tailwind in Q4 2025, but management also said FX and tariffs pressured margins. That is common in globally distributed tools businesses. Revenue translation can look better while cost absorption looks worse. The broader macro setup is mixed but improving: biopharma funding and M&A have strengthened, yet public and academic demand remains softer. That argues for gradual recovery rather than a straight-line rebound.

Balance Sheet Health

Income Statement Strength

Estimates Outlook

Valuation Assessment

Target Prices & Recommendation

Closing

Revvity is a good business in the middle of a sensible transition. The company has balanced segment exposure, a strong recurring revenue base, solid free cash flow, and a software asset that can become more important over time. Q4 2025 and Q1 2026 both showed that management is executing well enough to grow through a noisy backdrop. Diagnostics is carrying more of the load today, while Life Sciences looks closer to stabilization than deterioration.

The investment case does not require perfection. It requires steady execution, continued software traction, margin help from cost actions, and a cleaner portfolio after the China Immunodiagnostics divestiture. Those conditions are already partly visible in the numbers. With a fair value estimate of $108 and a current setup that still leaves room for rerating, Revvity(RVTY) earns a Buy for investors looking 12 to 24 months ahead rather than chasing the next quarter’s noise.